Benitec Financial Statements From 2010 to 2025

BNTC Stock  USD 12.71  1.30  11.39%   
Benitec Biopharma financial statements provide useful quarterly and yearly information to potential Benitec Biopharma Ltd investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Benitec Biopharma financial statements helps investors assess Benitec Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Benitec Biopharma's valuation are summarized below:
Gross Profit
75 K
Market Capitalization
215.4 M
Enterprise Value Revenue
10.5 K
Revenue
K
Earnings Share
(5.51)
We have found one hundred twenty available fundamental signals for Benitec Biopharma Ltd, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Benitec Biopharma's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 136.9 M. The current year's Enterprise Value is expected to grow to about 118.3 M

Benitec Biopharma Total Revenue

184,680

Check Benitec Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Benitec Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 293.3 K, Interest Expense of 1.1 M or Selling General Administrative of 7.2 M, as well as many indicators such as Price To Sales Ratio of 302, Dividend Yield of 0.0 or PTB Ratio of 2.13. Benitec financial statements analysis is a perfect complement when working with Benitec Biopharma Valuation or Volatility modules.
  
Check out the analysis of Benitec Biopharma Correlation against competitors.

Benitec Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets49.3 M47 M24.8 M
Pretty Stable
Other Current LiabilitiesM3.8 M1.4 M
Slightly volatile
Total Current Liabilities5.9 M5.7 M2.3 M
Slightly volatile
Total Stockholder Equity44.6 M42.5 M22.6 M
Pretty Stable
Property Plant And Equipment Net517.7 K516.4 K423.1 K
Slightly volatile
Accounts Payable801.4 K1.6 M758.9 K
Slightly volatile
Cash61.4 M58.5 M24 M
Slightly volatile
Non Current Assets Total583.5 K616.4 K478.3 K
Slightly volatile
Cash And Short Term Investments61.4 M58.5 M24 M
Slightly volatile
Net Receivables195.8 K206.1 K699.1 K
Very volatile
Common Stock Total Equity85590065 M
Slightly volatile
Common Stock Shares Outstanding4.9 M4.7 M1.4 M
Slightly volatile
Liabilities And Stockholders Equity49.3 M47 M24.8 M
Pretty Stable
Other Current Assets480.1 K665.9 K426.3 K
Slightly volatile
Total LiabilitiesM5.7 M2.4 M
Slightly volatile
Property Plant And Equipment Gross2.2 M2.1 M801.6 K
Slightly volatile
Total Current Assets48.8 M46.5 M24.4 M
Pretty Stable
Common Stock85590065 M
Slightly volatile
Property Plant Equipment511.4 K705 K437.2 K
Slightly volatile
Net Tangible Assets172.7 K181.8 K16.4 M
Slightly volatile
Net Invested Capital57.1 M54.3 M21.1 M
Slightly volatile

Benitec Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization293.3 K308.7 K1.5 M
Slightly volatile
Selling General Administrative7.2 M7.7 M6.4 M
Slightly volatile
Total Revenue184.7 K194.4 K1.1 M
Very volatile
Other Operating Expenses13.6 M25.9 M12.7 M
Slightly volatile
Research Development18.8 M18 M8.1 M
Slightly volatile
Cost Of Revenue202 K124.2 K180.2 K
Pretty Stable
Total Operating Expenses13.5 M25.7 M12.5 M
Slightly volatile
Interest Income5.1 K5.4 K238.3 K
Slightly volatile
Reconciled Depreciation327 K394.4 K256.2 K
Slightly volatile
Selling And Marketing Expenses221.6 K249.3 K271.8 K
Slightly volatile

Benitec Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.1 M2.2 M10.5 M
Pretty Stable
Capital Expenditures150.1 K161.1 K163.9 K
Very volatile
End Period Cash Flow61.5 M58.6 M24 M
Slightly volatile
Depreciation253 K394.4 K201 K
Slightly volatile
Change To Netincome591.5 K409.5 K621.3 K
Very volatile
Stock Based Compensation686.1 K954.5 K580 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio302491358
Slightly volatile
PTB Ratio2.132.2512.8626
Pretty Stable
Days Sales Outstanding524445700
Pretty Stable
Book Value Per Share3.183.35387
Slightly volatile
Average Payables493.1 K855 K665.3 K
Slightly volatile
Stock Based Compensation To Revenue4.13.463.0441
Slightly volatile
Capex To Depreciation0.70.60.7486
Very volatile
PB Ratio2.132.2512.8626
Pretty Stable
EV To Sales240281277
Slightly volatile
Payables Turnover0.08730.09190.3762
Pretty Stable
Sales General And Administrative To Revenue30.2727.9733.0214
Slightly volatile
Research And Ddevelopement To Revenue41.165.0445.9494
Slightly volatile
Capex To Revenue0.530.750.5824
Pretty Stable
Cash Per Share3.423.6360
Slightly volatile
Days Payables Outstanding2.6 K4.1 K2.9 K
Pretty Stable
Income Quality1.281.031.2385
Slightly volatile
Current Ratio14.5112.0716.0599
Slightly volatile
Tangible Book Value Per Share3.183.35387
Slightly volatile
Receivables Turnover0.810.853.9774
Very volatile
Graham Number10.2310.77921
Slightly volatile
Shareholders Equity Per Share3.183.35387
Slightly volatile
Debt To Equity0.00510.00540.217
Pretty Stable
Capex Per Share0.0120.01271.3869
Slightly volatile
Average Receivables46.3 K52.1 K56.8 K
Slightly volatile
Revenue Per Share0.01450.015311.3552
Slightly volatile
Interest Debt Per Share0.07990.08411.1159
Slightly volatile
Debt To Assets0.00470.00490.0397
Very volatile
Operating Cycle4234454.5 K
Slightly volatile
Price Book Value Ratio2.132.2512.8626
Pretty Stable
Days Of Payables Outstanding2.6 K4.1 K2.9 K
Pretty Stable
Ebt Per Ebit0.720.90.8785
Slightly volatile
Company Equity Multiplier0.940.992.4398
Pretty Stable
Total Debt To Capitalization0.00510.00540.0851
Pretty Stable
Debt Equity Ratio0.00510.00540.217
Pretty Stable
Quick Ratio13.8512.0715.2154
Slightly volatile
Net Income Per E B T0.790.880.9667
Slightly volatile
Cash Ratio12.8611.8814.421
Slightly volatile
Days Of Sales Outstanding524445700
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.111.161.0225
Slightly volatile
Price To Book Ratio2.132.2512.8626
Pretty Stable
Fixed Asset Turnover0.530.554.5248
Slightly volatile
Debt Ratio0.00470.00490.0397
Very volatile
Price Sales Ratio302491358
Slightly volatile
Asset Turnover0.00450.00480.0536
Very volatile
Price Fair Value2.132.2512.8626
Pretty Stable

Benitec Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap136.9 M135.6 M119.1 M
Slightly volatile
Enterprise Value118.3 M77.4 M99 M
Slightly volatile

Benitec Fundamental Market Drivers

Cash And Short Term Investments50.9 M

Benitec Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Benitec Biopharma Financial Statements

Benitec Biopharma stakeholders use historical fundamental indicators, such as Benitec Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Benitec Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Benitec Biopharma's assets and liabilities are reflected in the revenues and expenses on Benitec Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Benitec Biopharma Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.2 M-1.3 M
Total Revenue194.4 K184.7 K
Cost Of Revenue124.2 K202 K
Stock Based Compensation To Revenue 3.46  4.10 
Sales General And Administrative To Revenue 27.97  30.27 
Research And Ddevelopement To Revenue 65.04  41.10 
Capex To Revenue 0.75  0.53 
Revenue Per Share 0.02  0.01 
Ebit Per Revenue(119.74)(125.73)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:
Check out the analysis of Benitec Biopharma Correlation against competitors.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.51)
Revenue Per Share
0.003
Quarterly Revenue Growth
0.125
Return On Assets
(0.50)
Return On Equity
(0.92)
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.